Co-stimulatory agonists as immunological adjuvants

Vaccine

Volumn 24, Issue 17, 2006, Pages 3399-3407

  Barr, Tom A ^a   Carlring, Jennifer ^b   Heath, Andrew W ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adjuvant; CD28; CD40; Costimulatory

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD70 ANTIGEN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT ANTIGEN;

ANTINEOPLASTIC ACTIVITY; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD28; ANTIGENS, CD40; ANTIGENS, CD70; CD40 LIGAND; HUMANS; MEMBRANE PROTEINS; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORS;

EID: 33645215961     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.02.022     Document Type: Review

References (57)

1. C.A. Janeway Jr Approaching the asymptote? Evolution and revolution in immunology Cold Spring Harb Symp Quant Biol 54 1989 1 13
2. P. Matzinger The danger model: a renewed sense of self Science 296 2002 301 305
3. R. Medzhitov, and C.A. Janeway Jr Decoding the patterns of self and nonself by the innate immune system Science 296 2002 298 300
4. C. Merser, P. Sinay, and A. Adam Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives Biochem Biophys Res Commun 66 1975 1316 1322
5. E.B. Lindblad Aluminium adjuvants - in retrospect and prospect Vaccine 22 2004 3658 3668
6. T.A. Barr, P.L. Laing, and A.W. Heath Understanding and rational design of immunological adjuvants Innovations Pharma Technol 3 2003 71 79
7. R.L. Hunter Overview of vaccine adjuvants: present and future Vaccine 20 2002 S7 S12
8. T. Kaisho, and S. Akira Toll-like receptors as adjuvant receptors Biochim Biophys Acta 1589 2002 1 13
9. V.E. Schijns Immunological concepts of vaccine adjuvant activity Curr Opin Immunol 12 2000 456 463
10. D.M. Klinman, D. Currie, I. Gursel, and D. Verthelyi Use of CpG oligodeoxynucleotides as immune adjuvants Immunol Rev 199 2004 201 206
11. J. Gordon, and J.D. Pound Fortifying B cells with CD154: an engaging tale of many hues Immunology 100 2000 269 280
12. C. van Kooten, and J. Banchereau Functions of CD40 on B cells, dendritic cells and other cells Curr Opin Immunol 9 1997 330 337
13. L.S. Walker, A. Gulbranson-Judge, S. Flynn, T. Brocker, and P.J. Lane Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40 Immunol Today 21 2000 333 337
14. R.A. Kroczek, H.W. Mages, and A. Hutloff Emerging paradigms of T cell co-stimulation Curr Opin Immunol 16 2004 321 327
15. B.M. Carreno, and M. Collins The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses Annu Rev Immunol 20 2002 29 53
16. O. Acuto, and F. Michel CD28-mediated co-stimulation: a quantitative support for TCR signalling Nat Rev Immunol 3 2003 939 951
17. P. Dullforce, D.C. Sutton, and A.W. Heath Enhancement of T-cell independent immune responses in vivo by CD40 antibodies Nat Med 4 1998 88 91
18. T.A. Barr, and A.W. Heath Enhanced in vivo immune responses to bacterial lipopolysaccharide by exogenous CD40 stimulation Infect Immun 67 1999 3637 3640
19. L. Diehl, A.T. den Boer, S.P. Schoenberger, E.I. van der Voort, T.N. Schumacher, and C.J. Melief CD40 activation in vivo overcomes peptide induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy Nat Med 5 1999 774 779
20. R.R. French, H.T.C. Chan, A.L. Tutt, and M.J. Glennie CD40 antibody evokes a cytotoxic T cell response that eradicates lymphoma and bypasses T-cell help Nat Med 5 1999 548 553
21. S.P. Schoenberger, R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions Nature 393 1998 480 483
22. J.P. Ridge, F. Di Rosa, and P. Matzinger A conditioned dendritic cell can be a temporal bridge between a CD4 T-helper and a T-killer cell Nature 393 1998 474 478
23. S.R. Bennett, F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath Help for cytotoxic-T-cell responses is mediated by CD40 signalling Nature 393 1998 478 480
24. J. Carlring, T.A. Barr, A.L. McCormick, and A.W. Heath CD40 antibody as an adjuvant induces enhanced T cell responses Vaccine 22 2004 3323 3328
25. T.A. Barr, J. Carlring, and A.W. Heath CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens Vaccine 23 2005 3477 3482
26. A. Ninomiya, K. Ogasawara, K. Kajino, A. Takada, and H. Kida Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice Vaccine 20 2002 3123 3129
27. C.L. Ahonen, C.L. Doxsee, S.M. McGurran, T.R. Riter, W.F. Wade, and R.J. Barth Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN J Exp Med 199 2004 775 784
28. M.S. Rolph, and S.H. Kaufmann CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes J Immunol 166 2001 5115 5121
29. C.G.D. Vinuesa, I.C. MacLennan, M. Holman, and G.G. Klaus Anti-CD40 antibody enhances immune responses to polysaccharide without mimicking T cell help Eur J Immunol 29 1999 3216 3224
30. V. Bronte, S. Cingarlini, E. Apolloni, P. Serafini, I. Marigo, and C. De Santo Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase J Immunol 171 2003 6396 6405
31. T.A. Barr, A.L. McCormick, J. Carlring, and A.W. Heath A potent adjuvant effect of CD40 antibody attached to antigen Immunology 109 2003 87 92
32. J.L. Harcourt, M.P. Brown, L.J. Anderson, and R.A. Tripp CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice Vaccine 21 2003 2964 2979
33. S. Manoj, P.J. Griebel, L.A. Babiuk, and S. van Drunen Littel-van den Hurk Targeting with bovine CD154 enhances humoral immune responses induced by a DNA vaccine in sheep J Immunol 170 2003 989 996
34. R.A. Tripp, L. Jones, L.J. Anderson, and M.P. Brown CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse J Immunol 164 2000 5913 5921
35. M.G. Cusi, M.T. Del Vecchio, C. Terrosi, G.G. Savellini, G. Di Genova, and M. La Placa Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine J Immunol 174 2005 7210 7216
36. R. Xiang, F.J. Primus, J.M. Ruehlmann, A.G. Niethammer, S. Silletti, and H.N. Lode A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice J Immunol 167 2001 4560 4565
37. T.M. Foy, D.M. Shepherd, F.H. Durie, A. Aruffo, J.A. Ledbetter, and R.J. Noelle In vivo CD40-Gp39 interactions are essential for thymus-dependent humoral immunity. 2. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, Gp39 J Exp Med 178 1993 1567 1575
38. H.I. Huang, P.Y. Wu, C.Y. Teo, M.N. Chen, Y.C. Chen, and D. Silin Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand Int J Cancer 108 2004 696 703
39. W. Li Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen Immunology 115 2005 215 222
40. K. Sugamura, N. Ishii, and A. Weinberg Therapeutic targeting of the effector T-cell costimulatory molecule OX40 Nat Rev Immunol 4 2004 420 431
41. A.D. Weinberg, M.M. Rivera, R. Prell, A. Morris, T. Ramstad, and J.T. Vetto Engagement of the OX-40 receptor in vivo enhances antitumor immunity J Immunol 164 2000 2160 2169
42. P.Y. Pan, Y. Zang, K. Weber, M.L. Meseck, and S.H. Chen OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases Mol Ther 6 2002 528 536
43. I.R. Humphreys, L. Edwards, G. Walsl, A.J. Rae, G. Dougan, and S. Hill OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia J Immunol 170 2003 6125 6132
44. D.W. Grosenbach, J. Schlom, L. Gritz, A. Gomez Yafal, and J.W. Hodge A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production Cell Immunol 222 2003 45 57
45. S. Yang, J.W. Hodge, D.W. Grosenbach, and J. Schlom Vaccines with enhanced costimulation maintain high avidity memory CTL J Immunol 175 2005 3715 3723
46. J.L. Marshall, J.L. Gulley, P.M. Arlen, P.K. Beetham, K.Y. Tsang, and R. Slack Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte macrophage colony-stimulating factor, in patients with carcinoembryonic antigen expressing carcinomas J Clin Oncol 23 2005 720 731
47. L. Diehl, G.J. van Mierlo, A.T. den Boer, E. van der Voort, M. Fransen, and L. van Bostelen In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway J Immunol 168 2002 3755 3762
48. J. Bukczynski, T. Wen, K. Ellefsen, J. Gauldie, and T.H. Watts Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses Proc Natl Acad Sci USA 101 2004 1291 1296
49. C. Dohring, L. Angman, G. Spagnoli, and A. Lanzavecchia T helper cell-independent and accessory-cell-independent cytotoxic responses to human tumor-cells transfected with a B7 retroviral vector Int J Cancer 57 1994 754 759
50. L.P. Chen, P. McGowan, S. Ashe, J. Johnston, Y.W. Li, and I. Hellstrom Tumor immunogenicity determines the effect of B7 costimulation on T cell mediated tumor immunity J Exp Med 179 1994 523 532
51. R.M. Kalus, J.A. Kantor, L. Gritz, A.G. Yafal, G.P. Mazzara, and J. Schlom The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation Vaccine 17 1999 893 903
52. K. Sturmhoefel, K. Lee, G.S. Gray, J. Thomas, R. Zollner, and M. O'Toole Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant Cancer Res 59 1999 4964 4972
53. D. Yin, L. Zhang, R. Wang, L. Radvanyi, C. Haudenschild, and Q. Fang Ligation of CD28 in vivo induces CD40 ligand expression and promotes B cell survival J Immunol 163 1999 4328 4334
54. J. Carlring, T. Barr, A.M. Buckle, and A.W. Heath Anti-CD28 has a potent adjuvant effect on the antibody response to soluble antigens mediated through CTLA4 by-pass Eur J Immunol 33 2003 135 142
55. A.A. Hurwitz, T.F.Y. Yu, D.R. Leach, and J.P. Allison CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony stimulating factor for treatment of an experimental mammary carcinoma Proc Natl Acad Sci USA 95 1998 10067 10071
56. C. Haas, M. Lulei, P. Forunier, A. Arnold, and V. Schirrmacher T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine Vaccine 23 2005 2439 2453
57. T.F. Rowley, and A. Al-Shamkhani Stimulation by soluble CD70 promotes strong primary and secondary CD8 cytotoxic T cell responses in vivo J Immunol 172 2004 6039 6046